BackNeuroSense Therapeutics Ltd - Warrants (09/11/2026) Overview
NeuroSense Therapeutics Ltd - Warrants (09/11/2026)

NeuroSense Therapeutics Ltd - Warrants (09/11/2026) Return on Equity

Latest ROE for NeuroSense Therapeutics Ltd - Warrants (09/11/2026): 713.14% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

ROE

713.14%

Return on Equity

713.14%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

Average ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

NeuroSense Therapeutics Ltd - Warrants (09/11/2026) (NRSNW) FAQ

The latest ROE for NRSNW is 713.14%. That is above the sector sector average of -5.87%. Investors often review this figure alongside NeuroSense Therapeutics Ltd - Warrants (09/11/2026)'s historical trend and sector peers before judging valuation or financial health.

Against its sector companies, NRSNW currently prints 713.14% for ROE, while the sector average sits near -5.87%. That is roughly 12252.0% above the sector mean. Large gaps often invite a closer look at NeuroSense Therapeutics Ltd - Warrants (09/11/2026)'s growth, margins, and balance sheet.

Return on Equity shows how effectively NeuroSense Therapeutics Ltd - Warrants (09/11/2026) converts resources into returns. At 713.14%, NRSNW may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting NRSNW's ROE (713.14%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.